Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

Cytarabine 22Mitoxantrone 7Etoposide 7Idarubicin 6tipifarnib 4Filgrastim 4Topotecan 3Sorafenib 3Lenalidomide 3Daunorubicin 3Cyclophosphamide 3Clofarabine 3Bortezomib 3Azacitidine 3veliparib 2tanespimycin 2fludarabine phosphate 2alvocidib 2Imatinib Mesylate 2Everolimus 2Carboplatin 2Arsenic Trioxide 2trebananib 1romidepsin 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1ispinesib 1entinostat 1eltrombopag 1choline magnesium trisalicylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelomonocytic, Acute × choline magnesium trisalicylate × Clear all
NCT00156299 2013-11-19

Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate

Rutgers, The State University of New Jersey

Phase 1 Terminated
15 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡